These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 33038489)

  • 1. Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma.
    López-Cánovas JL; Del Rio-Moreno M; García-Fernandez H; Jiménez-Vacas JM; Moreno-Montilla MT; Sánchez-Frias ME; Amado V; L-López F; Fondevila MF; Ciria R; Gómez-Luque I; Briceño J; Nogueiras R; de la Mata M; Castaño JP; Rodriguez-Perálvarez M; Luque RM; Gahete MD
    Cancer Lett; 2021 Jan; 496():72-83. PubMed ID: 33038489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances.
    Fuentes-Fayos AC; Pérez-Gómez JM; G-García ME; Jiménez-Vacas JM; Blanco-Acevedo C; Sánchez-Sánchez R; Solivera J; Breunig JJ; Gahete MD; Castaño JP; Luque RM
    J Exp Clin Cancer Res; 2022 Jan; 41(1):39. PubMed ID: 35086552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer.
    Jiménez-Vacas JM; Herrero-Aguayo V; Gómez-Gómez E; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Fuentes-Fayos AC; Martínez-López A; Sánchez-Sánchez R; González-Serrano T; López-Ruiz DJ; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
    Transl Res; 2019 Oct; 212():89-103. PubMed ID: 31344348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug.
    Alors-Perez E; Blázquez-Encinas R; Alcalá S; Viyuela-García C; Pedraza-Arevalo S; Herrero-Aguayo V; Jiménez-Vacas JM; Mafficini A; Sánchez-Frías ME; Cano MT; Abollo-Jiménez F; Marín-Sanz JA; Cabezas-Sainz P; Lawlor RT; Luchini C; Sánchez L; Sánchez-Hidalgo JM; Ventura S; Martin-Hijano L; Gahete MD; Scarpa A; Arjona-Sánchez Á; Ibáñez-Costa A; Sainz B; Luque RM; Castaño JP
    J Exp Clin Cancer Res; 2021 Dec; 40(1):382. PubMed ID: 34857016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Splicing Factor 3b Subunit 1 (SF3B1) Reduced Cell Proliferation, Induced Apoptosis and Resulted in Cell Cycle Arrest by Regulating Homeobox A10 (HOXA10) Splicing in AGS and MKN28 Human Gastric Cancer Cells.
    Zhang Y; Yuan Z; Jiang Y; Shen R; Gu M; Xu W; Gu X
    Med Sci Monit; 2020 Jan; 26():e919460. PubMed ID: 31927557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of SF3B1 inhibits cell proliferation, invasion and migration triggering apoptosis in breast cancer via aberrant splicing.
    Zhang L; Zhang X; Zhang H; Liu F; Bi Y; Zhang Y; Cheng C; Liu J
    Breast Cancer; 2020 May; 27(3):464-476. PubMed ID: 31919642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
    Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
    EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transmembrane protein 106C promotes the development of hepatocellular carcinoma.
    Luo X; Han G; Lu R; Guan S; Wang Y; Ju L; Chen L; Shao J; Bian Z
    J Cell Biochem; 2020 Nov; 121(11):4484-4495. PubMed ID: 32037603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma.
    Yea S; Narla G; Zhao X; Garg R; Tal-Kremer S; Hod E; Villanueva A; Loke J; Tarocchi M; Akita K; Shirasawa S; Sasazuki T; Martignetti JA; Llovet JM; Friedman SL
    Gastroenterology; 2008 May; 134(5):1521-31. PubMed ID: 18471523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uridine-cytidine kinase 2 upregulation predicts poor prognosis of hepatocellular carcinoma and is associated with cancer aggressiveness.
    Huang S; Li J; Tam NL; Sun C; Hou Y; Hughes B; Wang Z; Zhou Q; He X; Wu L
    Mol Carcinog; 2019 Apr; 58(4):603-615. PubMed ID: 30556610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long noncoding RNA ZFPM2-AS1 acts as a miRNA sponge and promotes cell invasion through regulation of miR-139/GDF10 in hepatocellular carcinoma.
    He H; Wang Y; Ye P; Yi D; Cheng Y; Tang H; Zhu Z; Wang X; Jin S
    J Exp Clin Cancer Res; 2020 Aug; 39(1):159. PubMed ID: 32795316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-27b exerts an oncogenic function by targeting Fbxw7 in human hepatocellular carcinoma.
    Sun XF; Sun JP; Hou HT; Li K; Liu X; Ge QX
    Tumour Biol; 2016 Nov; 37(11):15325-15332. PubMed ID: 27704356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MEG2 inhibits the growth and metastasis of hepatocellular carcinoma by inhibiting AKT pathway.
    Ying D; Ruan Y; Zhou X
    Gene; 2019 Mar; 687():1-8. PubMed ID: 30399427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. cIAP2 via NF-κB signalling affects cell proliferation and invasion in hepatocellular carcinoma.
    Jiang XJ; Chen ZW; Zhao JF; Liao CX; Cai QH; Lin J
    Life Sci; 2021 Feb; 266():118867. PubMed ID: 33310033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring Splicing Modulation as an Innovative Approach to Combat Pancreatic Cancer: SF3B1 Emerges as a Prognostic Indicator and Therapeutic Target.
    Sciarrillo R; Terrana F; Comandatore A; Supadmanaba IGP; Wang B; Hassouni BE; Mantini G; Jansen G; Avan A; Carbone D; Diana P; Peters GJ; Morelli L; Cloos J; Assaraf YG; Giovannetti E
    Int J Biol Sci; 2024; 20(8):3173-3184. PubMed ID: 38904016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SF3B4 is regulated by microRNA-133b and promotes cell proliferation and metastasis in hepatocellular carcinoma.
    Liu Z; Li W; Pang Y; Zhou Z; Liu S; Cheng K; Qin Q; Jia Y; Liu S
    EBioMedicine; 2018 Dec; 38():57-68. PubMed ID: 30391496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma.
    Wang J; Xia C; Pu M; Dai B; Yang X; Shang R; Yang Z; Zhang R; Tao K; Dou K
    Oncol Rep; 2018 Oct; 40(4):1875-1884. PubMed ID: 30015982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long noncoding RNA LINC00324 exerts protumorigenic effects on liver cancer stem cells by upregulating fas ligand via PU box binding protein.
    Gao J; Dai C; Yu X; Yin XB; Zhou F
    FASEB J; 2020 Apr; 34(4):5800-5817. PubMed ID: 32128906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long non-coding RNA muskelin 1 antisense RNA (MKLN1-AS) is a potential diagnostic and prognostic biomarker and therapeutic target for hepatocellular carcinoma.
    Guo C; Zhou S; Yi W; Yang P; Li O; Liu J; Peng C
    Exp Mol Pathol; 2021 Jun; 120():104638. PubMed ID: 33878313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. lncRNA DRHC inhibits proliferation and invasion in hepatocellular carcinoma via c-Myb-regulated MEK/ERK signaling.
    Zhuang R; Zhang X; Lu D; Wang J; Zhuo J; Wei X; Ling Q; Xie H; Zheng S; Xu X
    Mol Carcinog; 2019 Mar; 58(3):366-375. PubMed ID: 30362626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.